UA103015C2 - Новые производные инсулина с чрезвычайно замедленным профилем время/действие - Google Patents

Новые производные инсулина с чрезвычайно замедленным профилем время/действие

Info

Publication number
UA103015C2
UA103015C2 UAA201009821A UAA201009821A UA103015C2 UA 103015 C2 UA103015 C2 UA 103015C2 UA A201009821 A UAA201009821 A UA A201009821A UA A201009821 A UAA201009821 A UA A201009821A UA 103015 C2 UA103015 C2 UA 103015C2
Authority
UA
Ukraine
Prior art keywords
amino acid
action profile
radical
novel insulin
delayed time
Prior art date
Application number
UAA201009821A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Пауль ХАБЕРМАНН
Герхард ЗАЙПКЕ
Роланд КУРРЛЕ
Гюнтер Мюллер
Марк ЗОММЕРФЕЛЬД
Норберт Теннагельс
Георг ЧАНК
Ульрих ВЕРНЕР
Original Assignee
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх
Priority claimed from PCT/EP2009/000017 external-priority patent/WO2009087081A2/de
Publication of UA103015C2 publication Critical patent/UA103015C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201009821A 2008-01-09 2009-01-06 Новые производные инсулина с чрезвычайно замедленным профилем время/действие UA103015C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200810003568 DE102008003568A1 (de) 2008-01-09 2008-01-09 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PCT/EP2009/000017 WO2009087081A2 (de) 2008-01-09 2009-01-06 Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil

Publications (1)

Publication Number Publication Date
UA103015C2 true UA103015C2 (ru) 2013-09-10

Family

ID=40758369

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201009821A UA103015C2 (ru) 2008-01-09 2009-01-06 Новые производные инсулина с чрезвычайно замедленным профилем время/действие

Country Status (3)

Country Link
CR (1) CR11511A (es)
DE (1) DE102008003568A1 (es)
UA (1) UA103015C2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
CA2747197A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
EP2370460B1 (en) 2008-12-15 2014-04-30 Zealand Pharma A/S Glucagon analogues
CN102282166B (zh) 2008-12-15 2015-04-01 西兰制药公司 胰高血糖素类似物
UA104766C2 (uk) 2009-07-13 2014-03-11 Зіленд Фарма А/С Ацильовані аналоги глюкагону
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
WO2011012718A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Prodrugs comprising an insulin linker conjugate
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
CN103068841A (zh) 2010-06-24 2013-04-24 西兰制药公司 胰高血糖素类似物
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
LT2854841T (lt) 2012-06-04 2017-06-12 Diamedica Inc. Kalikreino 1 iš žmogaus audinio glikozilinimo izoformos
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
SG11201602965WA (en) 2013-10-17 2016-05-30 Zealand Pharma As Acylated glucagon analogues
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
AU2015206890B2 (en) 2014-01-20 2019-05-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. DOSAGE FORMS OF TISSUE KALLIKREIN 1
EP3604328A4 (en) 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
IL95495A (en) 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DE19947456A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
PL1926749T3 (pl) 2005-09-14 2011-12-30 Sanofi Aventis Deutschland Cięcie prekursorów insuliny przez wariant trypsyny

Also Published As

Publication number Publication date
DE102008003568A1 (de) 2009-07-16
CR11511A (es) 2010-09-13

Similar Documents

Publication Publication Date Title
TN2010000298A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
WO2009087082A3 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
SG191069A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
NZ743910A (en) Purification of iduronate-2-sulfatase
EA019203B9 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
MX2020004912A (es) Compuestos derivados de prostaciclinas, y el uso de los mismo para el tratamiento de la hipertension pulmonar.
MX2015011243A (es) Peptidos para su uso en el tratamiento topico de enfermedades neurodegenerativas retinianas, en particular en fases de tempranas de retinopatia diabetica y otras enfermedades retinianas en las cuales la neurodegeneracion desempeña una funcion esencial.
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
MX2010004571A (es) Composiciones y metodos que comprenden peptidos y proteasas de aminoacidos basicos.
CA2651990C (en) Improved antimicrobial peptides
WO2010085700A3 (en) Treatment for obesity
NZ595242A (en) Improved anti-serum albumin binding variants
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
IN2014DN09367A (es)
BR112014013367A2 (pt) polipeptídeo
WO2013151467A3 (ru) Способ получения рекомбинантного пептида и полученный пептид
BR112017019241A2 (pt) análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico
WO2011061720A3 (en) Viral citrullinated peptides and uses thereof
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
MX2010011055A (es) Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
EA201101285A1 (ru) Антагонистические пептиды к frizzled-1 и frizzled-2 рецепторам
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile